Blood coagulation disease
MONDO:0001531A condition in which there is a deviation from or interruption of the normal coagulation properties of the blood.
Also known as: blood coagulation disorder, coagulation defect, coagulation disorder, coagulation disorder, blood, coagulation disorders, blood, coagulopathy, disorder, blood coagulation, disorders, blood coagulation
541 clinical trials for this condition and its sub-types, 54 tagged with Blood coagulation disease itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Blood coagulation disease
-
Inherited blood coagulation disorder 8 trials · 323 incl. sub-types
39 sub-types
- Hemophilia A 180 trials Sub-types →
- Hemophilia B 84 trials · 91 incl. sub-types Sub-types →
- Hereditary von Willebrand disease 18 trials · 29 incl. sub-types Sub-types →
- Inherited thrombophilia 0 trials · 28 incl. sub-types Sub-types →
- Hereditary hemolytic uremic syndrome 0 trials · 19 incl. sub-types Sub-types →
- Wiskott-Aldrich syndrome 10 trials
- Glanzmann thrombasthenia 8 trials Sub-types →
- Platelet-type bleeding disorder 10 8 trials
- Congenital thrombotic thrombocytopenic purpura 5 trials
- Hereditary thrombocytopenia and hematologic cancer predisposition syndrome 1 trial · 5 incl. sub-types Sub-types →
- Hermansky-Pudlak syndrome 4 trials Sub-types →
- Congenital vitamin K-dependent coagulation factors deficiency 0 trials · 4 incl. sub-types Sub-types →
- Congenital factor XII deficiency 1 trial
- Congenital plasminogen activator inhibitor type 1 deficiency 1 trial
- Hypoplasminogenemia 1 trial
- Ehlers-Danlos syndrome, fibronectinemic type 0 trials
- Scott syndrome 0 trials
- Tatsumi factor deficiency 0 trials
- Alpha-2-plasmin inhibitor deficiency 0 trials
- Congenital factor V deficiency 0 trials
- Congenital factor XI deficiency 0 trials
- Congenital high-molecular-weight kininogen deficiency 0 trials
- Cytosolic phospholipase-A2 alpha deficiency associated bleeding disorder 0 trials
- Dysplasminogenemia 0 trials
- Factor 5 and Factor VIII, combined deficiency of, 2 0 trials
- Factor V and factor VIII, combined deficiency of, type 1 0 trials
- Factor VII and Factor VIII, combined deficiency of 0 trials
- Factor XIII, A subunit, deficiency of 0 trials
- Factor XIII, b subunit, deficiency of 0 trials
- Familial thrombomodulin anomalies 0 trials
- Hereditary thrombocytosis with transverse limb defect 0 trials
- Hypercoagulability syndrome due to glycosylphosphatidylinositol deficiency 0 trials
- Inherited prekallikrein deficiency 0 trials
- Plasminogen deficiency, type II 0 trials
- Platelet-type bleeding disorder 12 0 trials
- Platelet-type bleeding disorder 14 0 trials
- Platelet-type bleeding disorder 16 0 trials
- Platelet-type bleeding disorder 18 0 trials
- Platelet-type bleeding disorder 8 0 trials
-
Coagulation protein disease 13 trials · 274 incl. sub-types
28 sub-types
- Hemophilia 55 trials · 216 incl. sub-types Sub-types →
- Von Willebrand disease (hereditary or acquired) 39 trials · 46 incl. sub-types Sub-types →
- Acquired coagulation factor deficiency 4 trials · 16 incl. sub-types Sub-types →
- Congenital fibrinogen deficiency 2 trials · 6 incl. sub-types Sub-types →
- Factor VII deficiency 6 trials Sub-types →
- Thrombophilia due to activated protein C resistance 5 trials
- Congenital vitamin K-dependent coagulation factors deficiency 0 trials · 4 incl. sub-types Sub-types →
- Factor X deficiency 2 trials Sub-types →
- Congenital factor XII deficiency 1 trial
- Congenital plasminogen activator inhibitor type 1 deficiency 1 trial
- Hypoplasminogenemia 1 trial
- East Texas bleeding disorder 0 trials
- Tatsumi factor deficiency 0 trials
- Alpha-2-plasmin inhibitor deficiency 0 trials
- Combined deficiency of factor V and factor VIII 0 trials Sub-types →
- Combined deficiency of factor VII and factor X 0 trials
- Congenital high-molecular-weight kininogen deficiency 0 trials
- Dysplasminogenemia 0 trials
- Factor V amsterdam bleeding disorder 0 trials
- Factor V atlanta bleeding disorder 0 trials
- Factor V deficiency 0 trials Sub-types →
- Factor V short isoforms-related bleeding disorder 0 trials
- Factor XIII deficiency 0 trials Sub-types →
- Hemorrhagic disease due to alpha-1-antitrypsin Pittsburgh mutation 0 trials
- Inherited prekallikrein deficiency 0 trials
- Multiple sclerosis-ichthyosis-factor VIII deficiency syndrome 0 trials
- Plasminogen deficiency, type II 0 trials
- Thrombomodulin-related bleeding disorder 0 trials
-
Thrombotic microangiopathy 26 trials · 151 incl. sub-types
2 sub-types
- Thrombocytopenic purpura 8 trials · 116 incl. sub-types Sub-types →
- Atypical hemolytic-uremic syndrome 19 trials Sub-types →
-
Thrombophilia 12 trials · 75 incl. sub-types
4 sub-types
- Inherited thrombophilia 0 trials · 28 incl. sub-types Sub-types →
- Thrombotic thrombocytopenic purpura 15 trials · 20 incl. sub-types Sub-types →
- Disseminated intravascular coagulation 15 trials Sub-types →
- Protein S deficiency 3 trials Sub-types →
-
Hemolytic-uremic syndrome 7 trials · 24 incl. sub-types
2 sub-types
- Hereditary hemolytic uremic syndrome 0 trials · 19 incl. sub-types Sub-types →
- Infection-related hemolytic uremic syndrome 0 trials · 2 incl. sub-types Sub-types →
-
Hemorrhagic disease of newborn 1 trial
-
Marantic endocarditis 0 trials
-
Prekallikrein deficiency 0 trials
1 sub-type
- Inherited prekallikrein deficiency 0 trials
Most studied deeper sub-types
-
Can a single gene shot free hemophilia b patients from regular infusions?
Cure Stopped earlyThis trial tests a gene therapy called FLT180a in adults with hemophilia B, a condition where the body lacks a clotting protein. The therapy delivers a working gene to help the body produce its own clotting factor. A small group of participants will receive a single dose and be f…
Phase 1/2 • Sponsor: Spur Therapeutics • Aim: Cure
Last updated Aug 02, 2026 00:00 UTC
-
Can a clotting boost make surgery safer for hemophilia patients?
Disease control Stopped earlyThis trial tests whether a medication called eptacog beta can safely prevent excessive bleeding in people with hemophilia A or B who have inhibitors and need major surgery. Participants receive the drug during and after their operation, and doctors measure how well bleeding is co…
Phase 3 • Sponsor: Laboratoire français de Fractionnement et de Biotechnologies • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Clotting drug may replace plasma transfusions in heart surgery
Disease control Stopped earlyThis study compared two treatments to reduce bleeding after heart valve surgery: a concentrated clotting drug (PCC) versus fresh frozen plasma (FFP). The trial planned to enroll 476 adults undergoing elective valve surgery. It was terminated early, so the full comparison was not …
Phase 4 • Sponsor: SHI Jia • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Gene-Edited cells aim to stop bleeding in severe hemophilia b
Disease control Stopped earlyThis early-stage trial tests a one-time treatment called BE-101 for adults with severe hemophilia B. The therapy uses a person's own blood cells, modified with CRISPR gene editing, to continuously produce the missing clotting factor. The goal is to reduce or prevent bleeding epis…
Phase 1/2 • Sponsor: Be Biopharma • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Tailored drug regimen shows promise for rare blood disorder
Disease control Stopped earlyThis study tested whether giving the drug caplacizumab based on regular blood tests (ADAMTS13 activity) could improve outcomes for adults with acquired thrombotic thrombocytopenic purpura (aTTP), a rare condition causing dangerous blood clots. The trial enrolled 58 adults and mon…
Phase 2 • Sponsor: University Hospital, Rouen • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Hemophilia drug study falls short: only 3 patients enrolled before termination
Disease control Stopped earlyThis study aimed to see if a new medicine (efanesoctocog alfa) helps people with moderate or severe hemophilia A reach their personal goals and be more physically active. It planned to enroll 35 people aged 12 to 50, but was stopped early after only 3 joined. The medicine is used…
Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Promising aHUS drug trial stalls after only 6 patients enrolled
Disease control Stopped earlyThis study tested a drug called narsoplimab (OMS721) for atypical hemolytic uremic syndrome (aHUS), a rare condition that causes blood clots and organ damage. The trial aimed to see if the drug could improve platelet counts and was safe for adults and adolescents. However, the st…
Phase 3 • Sponsor: Omeros Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Experimental drug iptacopan tested for rare blood disorders
Disease control Stopped earlyThis study tested an experimental drug called iptacopan in people with two rare blood disorders: immune thrombocytopenia (ITP) and cold agglutinin disease (CAD). The goal was to see if the drug could improve platelet counts in ITP or hemoglobin levels in CAD. The trial was termin…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Cancer drug combo shows promise for Hard-to-Treat bowel cancer
Disease control Stopped earlyThis study tested a combination of two drugs, atezolizumab and bevacizumab, in 46 people with advanced colorectal cancer that had stopped responding to chemotherapy and had a specific genetic feature called MSI-like. The goal was to see if the treatment could shrink tumors. The s…
Phase 2 • Sponsor: Vall d'Hebron Institute of Oncology • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Gene Editing's lasting impact: a 10-Year safety watch
Knowledge-focused Stopped earlyThis study checks on people who previously received gene editing for hemophilia B or mucopolysaccharidosis (MPS) I or II. No new treatment is given; instead, participants are monitored for up to 10 years to see if any new health problems or worsening of existing conditions appear…
Sponsor: Sangamo Therapeutics • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Could home blood tests transform hemophilia care? study seeks patient views
Knowledge-focused Stopped earlyThis study looked at how patients with hemophilia A or those on blood thinners feel about monitoring their blood clotting at home. Researchers interviewed 19 people to understand their needs and hopes for a new device that could measure clotting factors. The goal was to gather in…
Sponsor: Radboud University Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Simple blood test may predict Post-Surgery clot risk
Knowledge-focused Stopped earlyThis pilot study aimed to see if a blood test called thromboelastography (TEG) and platelet mapping could predict clotting or bleeding complications after non-cardiac surgery. The study included 200 patients who were taking aspirin or clopidogrel for at least 10 days before elect…
Sponsor: McMaster University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Tiny study on clotting disorder and artery health ends early
Knowledge-focused Stopped earlyThis study aimed to see if women with thrombophilia (a condition that makes blood clot more easily) have differences in artery function compared to healthy women. Researchers planned to measure blood vessel dilation and other artery health markers. However, the study was terminat…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC